APVO - Aptevo Therapeutics Inc.
| Previous Close | 0.8100 |
| Open | 0.7800 |
| Bid | 0.6500 x 800 |
| Ask | 0.0000 x 1400 |
| Day's Range | 0.7800 - 0.8200 |
| 52 Week Range | 0.4900 - 5.7300 |
| Volume | 218,630 |
| Avg. Volume | 636,892 |
| Market Cap | 35.177M |
| Beta (3Y Monthly) | 2.45 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7620 |
| Earnings Date | Aug 9, 2019 - Aug 9, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.67 |
- GlobeNewswire
Aptevo Therapeutics Reports Second Quarter 2019 Financial Results
Reports Positive Preliminary Top-Line Safety Data for APVO210Phase 1 Single Ascending Dose (SAD) Clinical Study Advances APVO210 into Phase 1 Multiple Ascending Dose (MAD).
- GlobeNewswire
Aptevo Therapeutics Receives $4.3 Million Milestone Payment From Saol International Limited
Aptevo Therapeutics Inc. (APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today the receipt of a $4.3 million milestone payment from Saol International Limited (Saol). This performance-based milestone has been collected more than one year earlier than anticipated in the original contract between Aptevo and Saol. “The $4.3 million milestone payment from Saol provides additional non-dilutive capital for our business as we aim to achieve important near-term milestones in both our clinical and commercial programs in 2019 and 2020,” said Jeff Lamothe, Chief Financial Officer for Aptevo.
- GlobeNewswire
Aptevo Therapeutics Reports Continued Progress In APVO210 and APVO436 Clinical Trials
Aptevo Therapeutics Inc. (APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, announced today that it has completed dosing in a single ascending dose (SAD) Phase 1 study of APVO210, a novel investigational bispecific antibody candidate being developed for the treatment of autoimmune diseases. Preliminary data from the SAD study show that single ascending doses of APVO210 did not cause any adverse events of concern or dose-limiting toxicities, nor were any anti-drug antibodies observed in the study based on patient samples obtained to date. As a result, Aptevo has received approval to begin the next phase of the study, evaluating multiple ascending doses of APVO210 in healthy volunteers.
- GlobeNewswire
Aptevo Therapeutics Launches New 3000 IU IXINITY Assay Offering Enhanced User Experience and Improved Convenience for Hemophilia B Patients
Aptevo Therapeutics Inc. (APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced that it has launched a new, larger 3000 IU (international unit) vial size for IXINITY® [Coagulation Factor IX (Recombinant)] into the U.S. market. The new 3000 IU assay offers important advantages for both patients and channel partners, which Aptevo anticipates will help drive future conversions to IXINITY therapy. “We are excited to continue to deliver on our promise to patients with this latest initiative,” said Jeff Lamothe, Chief Financial Officer for Aptevo.
- GlobeNewswire
Aptevo Therapeutics Reports First Quarter 2019 Financial Results
Achieves 73% Increase in First Quarter 2019 Year-Over-Year IXINITY® Net Revenue On Target for Launch of New 3,000 IU IXINITY Assay Mid-2019 Advances Enrollment in APVO436 and.
- Zacks
The Zacks Analyst Blog Highlights: Advanced Emissions, Aptevo, BankFinancial, Good Times and Health Insurance
The Zacks Analyst Blog Highlights: Advanced Emissions, Aptevo, BankFinancial, Good Times and Health Insurance
- Zacks
5 Stocks to Gain From Dollar's Recent Strength
The U.S. dollar hits an almost 2-year record high as global central banks turn dovish and German business moral deteriorates.
- GlobeNewswire
Aptevo Therapeutics Reports IXINITY® and Pipeline Progress
Aptevo Therapeutics Inc. (APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced continued progress in the Company’s commercial and clinical development programs, reporting first quarter 2019 IXINITY net revenue of $7.0 million, which represents a 73% increase from the first quarter of 2018. Additionally, Aptevo announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for a Prior Approval Supplement (PAS) describing plans for the manufacture of a new 3,000 IU assay and remains on track to begin supplying the market with 3,000 IU IXINITY vials in mid-2019. Importantly, we also continue to project that our cash burn rate in 2019 will be in the range of $36-40 million, a 33% reduction compared to our projected burn rate in 2018 of between $55-60 million. For several reasons, we believe 2019 has the potential to be a transformative year for Aptevo as the first clinical data begins to emerge for our next-generation ADAPTIR™ programs, which have shown promising differentiation in preclinical studies. I look forward to keeping our shareholders updated on our progress as we reach key milestones in both our ADAPTIR and IXINITY programs this year,” said Marvin L. White, President and Chief Executive Officer.
- Simply Wall St.
What Kind Of Investor Owns Most Of Aptevo Therapeutics Inc. (NASDAQ:APVO)?
If you want to know who really controls Aptevo Therapeutics Inc. (NASDAQ:APVO), then you'll have to look at the makeup of its share registry. Large companies usually have institutions as shareholders, and we usually see insiders ow...
- GlobeNewswire
Aptevo Therapeutics Presents New Preclinical Data for APVO436 and ALG.APV-527 at the American Association for Cancer Research 2019 Annual Meeting
Aptevo Therapeutics Inc. (APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, announced today that new preclinical data for two ADAPTIR bispecific candidates, APVO436, a bispecific antibody candidate targeting CD123 and CD3, and ALG.APV-527, a bispecific antibody candidate targeting 4-1BB and 5T4, were presented at the American Association for Cancer Research (AACR) 2019 Annual Meeting.
- GlobeNewswire
Aptevo Therapeutics to Present New Preclinical Data for APVO436 and ALG.APV.527 at the American Association for Cancer Research 2019 Annual Meeting
SEATTLE, March 25, 2019 -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today.
- GlobeNewswire
Aptevo Therapeutics Begins Phase 1 Clinical Trial of APVO210 a Novel Bispecific Antibody for the Treatment of Autoimmune and Inflammatory Diseases
Aptevo Therapeutics Inc. (APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, announced today that it has commenced dosing in a Phase 1 clinical trial of APVO210, a novel bispecific antibody candidate built on Aptevo’s ADAPTIR™ therapeutic protein platform which is being developed to treat autoimmune and inflammatory diseases. There is a growing body of data to support APVO210 as a novel, first-in-class targeted cytokine immunotherapy. Preclinical data published in the journal Frontiers in Immunology highlighted the activity of APVO210 as a potent and selective agent to generate a population of regulatory T cells that may play a key role in the suppression of inflammatory processes associated with pathogenic autoimmune and inflammatory conditions, such as psoriasis, inflammatory bowel disease, rheumatoid arthritis, graft-versus-host disease, and lupus, as well as other diseases where there is antigen-driven activation of T lymphocyte-mediated disease.
- GlobeNewswire
Aptevo Therapeutics Reports 2018 Financial Results and Provides Business Update
Achieves Record Annual IXINITY® Net Revenue of $23.1 Million Representing 111% Increase Over 2017 Advances APVO436 Into Phase 1/1b Clinical Trial for Treatment of Acute Myeloid.
- Zacks
Aptevo Therapeutics Inc. (APVO) Moves to Buy: Rationale Behind the Upgrade
Aptevo Therapeutics Inc. (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- GlobeNewswire
Aptevo Announces Pricing of $22 Million Offering of Common Stock and Warrants
SEATTLE, March 07, 2019 -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today.
- GlobeNewswire
Aptevo Announces Proposed Public Offering of Common Stock and Warrants
Aptevo Therapeutics Inc. (APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and accompanying warrants to purchase shares of common stock in an underwritten public offering. All of the securities to be sold in the offering will be offered by Aptevo. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Piper Jaffray is acting as sole book-running manager for the offering.
- GlobeNewswire
Aptevo Therapeutics Highlights Key 2019 Priorities
ADAPTIR™ Bispecific Antibody Candidates Poised to Progress in Clinical Development APVO436 Advancing in Phase 1 Clinical Trial for Acute Myeloid Leukemia;APVO210 Beginning.
- GlobeNewswire
Aptevo Therapeutics Collects $3.3 Million In Escrow Funds From Saol Therapeutics
Aptevo Therapeutics Inc. (APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that it has collected $3.3 million in escrow funds from Saol Therapeutics related to a purchase agreement between the companies under which Saol Therapeutics acquired three hyperimmune products previously marketed by Aptevo, WinRho SDF, HepaGam B, and VARIZIG. The transaction, completed in September 2017 and valued at up to $74.5 million, included an upfront payment to Aptevo of $65 million, of which approximately $3.3 million was held in an escrow account. The escrow funds have now been collected in full by Aptevo, with no claims being made against it by Saol. In addition, Aptevo is also eligible to receive a potential milestone payment of up to $7.5 million from Saol related to the achievement of a gross profit milestone threshold. In addition, Aptevo may receive up to $2 million related to collection of certain accounts receivable from Saol.
- GlobeNewswire
Aptevo Therapeutics Announces Up To $35 Million Common Stock Purchase Agreement With Lincoln Park Capital
Aptevo Therapeutics Inc. (APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that it has entered into a common stock purchase agreement and registration rights agreement with Lincoln Park Capital (LPC) Fund, LLC, under which LPC has committed to purchase up to an aggregate of $35 million in Aptevo’s common stock over a 36-month term. Under the terms and conditions of the purchase agreement, and after the filing and effectiveness of a registration statement registering the shares to be sold to LPC, Aptevo has the right, in its sole discretion, to sell shares of common stock to LPC and LPC is obligated to purchase the common stock at times and amounts as set forth in the purchase agreement.
- Simply Wall St.
Need To Know: Aptevo Therapeutics Inc. (NASDAQ:APVO) Insiders Have Been Buying Shares
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examples Read More...
- GlobeNewswire
Aptevo Therapeutics Doses First Patient in Phase 1/1b Clinical Trial of Lead Next-Generation Bispecific Antibody APVO436
Aptevo Therapeutics Inc. (APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that the first patient has been dosed in a Phase 1/1b clinical trial of APVO436, a novel anti-CD123 by anti-CD3 bispecific antibody based on Aptevo’s ADAPTIR™ technology, which is being developed for the treatment of patients with Acute Myeloid Leukemia (AML) and High-Grade Myelodysplastic Syndrome (MDS). As a novel immunotherapy, APVO436 is designed to engage the immune system to mount a targeted response against CD123-expressing hematological tumors. Cytokine release syndrome (CRS) is a significant concern with T-cell activating therapies and has been associated with severe complications in clinical trials. In preclinical studies, APVO436 induced lower levels of several key T-cell cytokines, including IFNg, IL-2, IL-6, and TNFa. Aptevo believes that the improved cytokine activation profile observed in preclinical studies of APVO436 suggest that it could offer a potential safety advantage with reduced toxicities compared to other CD123 x CD3 T-cell engagers at comparable or higher doses.
- GlobeNewswire
United Parcel Service, Endurance International Group, Idera Pharmaceuticals, Aptevo Therapeutics, and Electro Scientific Industries — Future Expectations, Projections Moving into 2018
NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire
Aptevo Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference
SEATTLE, Nov. 20, 2018 -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced.
- GlobeNewswire
Aptevo Therapeutics Reports Third Quarter 2018 Financial Results
Achieves 132% Increase in IXINITY® Quarterly Net Revenue Year-Over-Year More than Doubles Year-to-Date IXINITY Net Revenue from $8.1 Million to $16.7 Million.
- GlobeNewswire
Alligator Bioscience and Aptevo Therapeutics Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting
Data Show That ALG.APV-527 Selectively Activates and Enhances Tumor-directed T-cell and Natural Killer (NK) Cell Responses Targets 5T4 Cancer Antigen Present on Many Types of.
